Our preclinical studies in a GC cancer model driven by the absence of NF-κB1, have shown that genetic deletion of IL-6 is dispensable for the development of GC, with a minor role for IL-6 at the early stages of gastric dysplasia (207). Here, IL6 is linked to cancer.